These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 3744133)

  • 21. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
    Harenberg J; Schmidt JA; Koppenhagen K; Tolle A; Huisman MV; Büller HR
    Thromb Haemost; 2000 May; 83(5):652-6. PubMed ID: 10823256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis.
    Luomanmäki K; Grankvist S; Hallert C; Jauro I; Ketola K; Kim HC; Kiviniemi H; Koskivirta H; Sörskog L; Vilkko P
    J Intern Med; 1996 Aug; 240(2):85-92. PubMed ID: 8810934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of deep venous thrombosis with low molecular weight heparin (Fragmin)].
    Nesvold A; Ly B; Abildgaard U; Stiris M
    Tidsskr Nor Laegeforen; 1991 Nov; 111(27):3296-7. PubMed ID: 1659751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties.
    Holmer E; Söderberg K; Bergqvist D; Lindahl U
    Haemostasis; 1986; 16 Suppl 2():1-7. PubMed ID: 3744129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes with unfractionated heparin monitored by anti-factor Xa vs. activated partial Thromboplastin time.
    Coons JC; Iasella CJ; Thornberg M; Fitzmaurice MG; Goehring K; Jablonski L; Leader D; Meyer A; Seo H; Benedict NJ; Smith RE
    Am J Hematol; 2019 Sep; 94(9):1015-1019. PubMed ID: 31243789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.
    Simonneau G; Charbonnier B; Decousus H; Planchon B; Ninet J; Sie P; Silsiguen M; Combe S
    Arch Intern Med; 1993 Jul; 153(13):1541-6. PubMed ID: 8391792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis.
    Harenberg J; Huck K; Bratsch H; Stehle G; Dempfle CE; Mall K; Blauth M; Usadel KH; Heene DL
    Haemostasis; 1990; 20 Suppl 1():205-19. PubMed ID: 1964663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.
    Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL
    Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heparin inhibits fibrin, but not leukocytes, in a model of deep-vein thrombosis.
    Simmons CA; Burdick MD; Schaub RG
    J Surg Res; 1987 Nov; 43(5):468-75. PubMed ID: 3682807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and pharmacodynamics of a therapeutic dose of unfractionated heparin (200 U/kg) administered subcutaneously or intravenously to healthy dogs.
    Diquélou A; Barbaste C; Gabaig AM; Trumel C; Abella-Bourges N; Guelfi JF; Bousquet Mélou A
    Vet Clin Pathol; 2005 Sep; 34(3):237-42. PubMed ID: 16134071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
    Pindur G; Heiden M; Köhler M
    Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of two regimens of low molecular weight heparin fragment (Fragmin) in preventing postoperative venous thrombolism.
    Kakkar VV; Kakkar S; Sanderson RM; Peers CE
    Haemostasis; 1986; 16 Suppl 2():19-24. PubMed ID: 3744132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of an algorithm for administering subcutaneous heparin in the treatment of deep venous thrombosis.
    Prandoni P; Bagatella P; Bernardi E; Girolami B; Rossi L; Scarano L; Marchiori A; Piccioli A; Girolami A
    Ann Intern Med; 1998 Aug; 129(4):299-302. PubMed ID: 9729183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
    Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin.
    Eriksson E; Wollter IM; Christenson B; Stigendal L; Risberg B
    Thromb Haemost; 1988 Apr; 59(2):284-8. PubMed ID: 2838926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.
    Monreal M; Lafoz E; Olive A; del Rio L; Vedia C
    Thromb Haemost; 1994 Jan; 71(1):7-11. PubMed ID: 8165649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Low molecular weight heparin versus unfractionated heparin in the treatment of deep venous thrombosis--a meta-analysis].
    Nielsen JD; Landorph A
    Ugeskr Laeger; 1994 Oct; 156(40):5844-9. PubMed ID: 7985276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg.
    Holmoström M; Berglund MC; Granquist S; Bratt G; Törnebohm E; Lockner D
    Thromb Res; 1992 Jul; 67(1):49-55. PubMed ID: 1332213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.